- Home
- GLRE vs LRMR Comparison
GLRE vs LRMR Comparison
Compare GLRE & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLRE | LRMR |
|---|---|---|
| Founded | 2004 | N/A |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.5M | 455.8M |
| IPO Year | 2007 | 2014 |
Fundamental Metrics
Financial Performance| Metric | GLRE | LRMR |
|---|---|---|
| Price | $18.55 | $4.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 232.1K | ★ 1.7M |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.00 | N/A |
| EPS | ★ 2.17 | N/A |
| Revenue | ★ $729,777,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,816.14 |
| P/E Ratio | $8.48 | ★ N/A |
| Revenue Growth | ★ 4.85 | N/A |
| 52 Week Low | $11.57 | $1.73 |
| 52 Week High | $19.25 | $6.42 |
Technical Indicators
Market Signals| Indicator | GLRE | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 69.85 | 52.09 |
| Support Level | $12.49 | $3.14 |
| Resistance Level | N/A | $5.36 |
| Average True Range (ATR) | 0.52 | 0.28 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 74.39 | 53.51 |
Price Performance
Historical ComparisonAbout GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.